Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placebo‐controlled SCALE Teens trial

Author:

Bensignor Megan O.1ORCID,Bramante Carolyn T.1ORCID,Bomberg Eric M.1ORCID,Fox Claudia K.1ORCID,Hale Paula M.2,Kelly Aaron S.1,Mamadi Rashmi3,Prabhu Nandana4,Harder‐Lauridsen Nina M.5,Gross Amy C.1ORCID

Affiliation:

1. Department of Pediatrics, Center for Pediatric Obesity Medicine University of Minnesota Minneapolis Minnesota USA

2. Clinical Development, Medical & Regulatory Affairs Novo Nordisk Inc. Plainsboro New Jersey USA

3. Global Medical Affairs Novo Nordisk Bangalore India

4. Biostatistics Novo Nordisk Bangalore India

5. Medical and Science Novo Nordisk A/S Søborg Denmark

Abstract

SummaryBackgroundAs childhood obesity prevalence increases, determining which patients respond to anti‐obesity medications would strengthen personalized approaches to obesity treatment. In the SCALE Teens trial among pubertal adolescents with obesity (NCT02918279), liraglutide 3.0 mg (or maximum tolerated dose) significantly reduced body mass index (BMI) standard deviation score on average versus placebo. That said, liraglutide effects on BMI reduction varied greatly among adolescents, similar to adults.ObjectivesTo identify post hoc characteristics predictive of achieving ≥5% and ≥10% BMI reductions at 56 weeks with liraglutide versus placebo in adolescents from the SCALE Teens trial.MethodsLogistic regression analysis was performed in 251 adolescents treated with liraglutide (n = 125) or placebo (n = 126) for 56 weeks. Baseline characteristics (selected a priori) included sex, race, ethnicity, age, Tanner (pubertal) stage, glycemic status (hyperglycemia [type 2 diabetes/prediabetes] vs. normoglycemia), obesity category (Class II/III vs. I), severity of depression symptoms (Patient Health Questionnaire‐9), and weight variability (weight fluctuations over time). The effects of early responder status (≥4% BMI reduction at week 16) on week 56 response were assessed using descriptive statistics.ResultsBaseline characteristics did not affect achievement of ≥5% and ≥10% BMI reductions at week 56 in adolescents treated with liraglutide. Further, there was no association between weight variability and BMI reduction. Early liraglutide responders appeared to have greater BMI and body weight reductions at week 56 compared with early non‐responders.ConclusionsThis secondary analysis suggests that adolescents with obesity may experience significant BMI reductions after 56 weeks of liraglutide treatment, regardless of their sex, race, ethnicity, age, pubertal stage, glycemic status, obesity category, severity of depression symptoms, or weight variability. Early response may predict greater week 56 response.

Funder

Novo Nordisk

Publisher

Wiley

Subject

Public Health, Environmental and Occupational Health,Nutrition and Dietetics,Health Policy,Pediatrics, Perinatology and Child Health

Reference42 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3